Ardent Animal Health marketed Acti-Stem Therapy and PureVet PRP as unapproved new animal drugs for dogs and cats.
What happened
FDA inspected Ardent’s Nicholasville, Kentucky facility from September 10 to September 13, 2024, then reviewed the company’s website, Facebook and Instagram pages, and phone app. FDA found claims that Acti-Stem Therapy and PureVet PRP treat or prevent disease in dogs and cats, which makes them new animal drugs (drugs not generally recognized as safe and effective for their labeled uses). FDA says the products are not approved or index listed (listed by FDA as legally marketable without approval), so marketing them is illegal.
What FDA found
FDA says the products are drugs because the company's claims say they diagnose, cure, mitigate, treat, or prevent disease in animals.
FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]FDA says the products are new animal drugs because they are not generally recognized as safe and effective for their labeled uses.
FD&C Act section 201(v) [21 U.S.C. § 321(v)]FDA says the products lack an approved new animal drug application, conditional approval, or index listing required for legal marketing.
FD&C Act sections 512, 571, and 572 [21 U.S.C. §§ 360b, 360ccc, 360ccc-1]FDA says the products are unsafe and adulterated because they are not approved or index listed.
FD&C Act section 512(a) [21 U.S.C. § 360b(a)] and section 501(a)(5) [21 U.S.C. § 351(a)(5)]FDA says introducing or delivering the products into interstate commerce is prohibited.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
Within 15 working days, Ardent must write to FDA’s Center for Veterinary Medicine explaining the specific corrections and steps to prevent recurrence, with related documentation. If corrections cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- veterinary clinics offering stem cell or PRP therapies
- animal health companies marketing regenerative products
- pet owners considering these therapies
This is a summary. Read the original letter on fda.gov.